Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar biofest (30.77) Submitted: 12/6/2009 3:19:13 PM : Outperform Start Price: $4.14 PGNX Score: +85.00

Speculative but possible cancer effect from pain drug.

Featured Broker Partners


Advertisement